RxDoctor Payments Data

Jeffrey Gallo, MD

Ophthalmology · Worcester, MANPI 1720013923

Payments from drug & device makers

$2,243in general payments, 2019–2025

Across 96 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • Novartis$231
  • Alcon$213
  • Bausch & Lomb Americas Inc.$204
  • Oyster Point Pharma, Inc.$194
  • Tarsus Pharmaceuticals, Inc.$180
  • plus $719 from 13 others

What the payments were for

  • Food & beverage$2,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,243 in reported general payments places this provider in the 60th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$295,837
Medicare patients
1,055
Services billed
3,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$64,964
XiidraLifitegrast38$31,353
MieboPerfluorohexyloctane/Pf18$16,394
Latanoprost1,300$14,690
LumiganBimatoprost32$14,313
RocklatanNetarsudil Mesylat/Latanoprost32$12,625
VyzultaLatanoprostene Bunod17$7,639
CombiganBrimonidine Tartrate/Timolol19$6,544
Brimonidine Tartrate259$4,764
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$4,335
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat159$3,269
Timolol Maleate279$2,851
Prednisolone Acetate67$2,026
Fluorometholone18$1,926
ValacyclovirValacyclovir Hcl27$865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$502$85,820109 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$204$55,38773 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$12,62532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →